Literature DB >> 7949746

Pharmacokinetic model of intravitreal drug injection.

K J Tojo1, A Ohtori.   

Abstract

A dynamic mathematical model is developed to describe the distribution and elimination behavior of a drug in the vitreous body following intravitreal injection. The effects of three elimination pathways--the annular gap between the lens and the ciliary body (the posterior chamber), the lens, and the retina-choroid-sclera membrane--upon the concentration distribution in the vitreous body and the time course of the rate of elimination have been quantitatively demonstrated. The effects of metabolism in the vitreous body and the site of injection are also simulated. The annular gap between the lens and the ciliary body (the posterior chamber) is found to be a main route of elimination for large molecules injected into the vitreous body. For small or highly lipophilic molecules, however, both the posterior chamber and the retina-choroid-sclera membrane act as major routes of elimination. The lens pathway may contribute negligibly to the escape of drugs from the vitreous body. The concentration on the surface of the retina is appreciably affected by the site of injection or the initial distribution profiles, while the concentration gradient on the lens surface remains almost independent of the site of injection. To maintain the therapeutic concentration in the vitreous body or in the retina for a prolonged period of time, the drug must be injected into the posterior area of the vitreous body. When the drug is injected into the anterior segment of the vitreous body, the drug molecules quickly escape into the posterior chamber from the annular gap between the lens and the ciliary body. The present mathematical model describes well in vivo elimination profile of lomefloxacin following intravitreal injection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949746     DOI: 10.1016/0025-5564(94)90018-3

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  7 in total

1.  Extended Pharmacokinetic Model of the Rabbit Eye for Intravitreal and Intracameral Injections of Macromolecules: Quantitative Analysis of Anterior and Posterior Elimination Pathways.

Authors:  Marko Lamminsalo; Ella Taskinen; Timo Karvinen; Astrid Subrizi; Lasse Murtomäki; Arto Urtti; Veli-Pekka Ranta
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

2.  Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep.

Authors:  Tugba Cakmak Argun; Ozlem Yalcin Tok; Levent Tok; Gulsen Yilmaz; Fatma Meric Yilmaz; Alime Gunes; Mehmet Argun; Osman Butuner
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

3.  Intravitreal kinetics of hesperidin, hesperetin, and hesperidin G: effect of dose and physicochemical properties.

Authors:  Ramesh Srirangam; Ketan Hippalgaonkar; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2012-01-06       Impact factor: 3.534

Review 4.  Ocular Fluid Mechanics and Drug Delivery: A Review of Mathematical and Computational Models.

Authors:  Ajay Bhandari
Journal:  Pharm Res       Date:  2021-12-22       Impact factor: 4.200

5.  FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Mol Vis       Date:  2009-12-16       Impact factor: 2.367

6.  Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy.

Authors:  Tobias Sonntag; Franziska Froemel; W Daniel Stamer; Andreas Ohlmann; Rudolf Fuchshofer; Miriam Breunig
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

7.  Extended Pharmacokinetic Model of the Intravitreal Injections of Macromolecules in Rabbits. Part 2: Parameter Estimation Based on Concentration Dynamics in the Vitreous, Retina, and Aqueous Humor.

Authors:  Marko Lamminsalo; Timo Karvinen; Astrid Subrizi; Arto Urtti; Veli-Pekka Ranta
Journal:  Pharm Res       Date:  2020-10-22       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.